At the start of this year's American Society of Clinical Oncology (ASCO) Annual Meeting, Merck Serono, a division of Merck KGaA, Darmstadt, Germany, presented a retrospective analysis of the CRYSTAL and OPUS trials which demonstrated that, by treating a specific population of metastatic bowel...